nach oben

Erschienen in:

01.01.2014 | Research Article

Association of myeloperoxidase with ovarian cancer

verfasst von: Dan Cacsire Castillo-Tong, Dietmar Pils, Georg Heinze, Ioana Braicu, Jalid Sehouli, Alexander Reinthaller, Eva Schuster, Andrea Wolf, Rafal Watrowski, Richard A. Maki, Robert Zeillinger, Wanda F. Reynolds

Erschienen in: Tumor Biology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Myeloperoxidase (MPO) is an oxidant generating enzyme normally restricted to myeloid cells, however aberrant MPO expression has been found to occur in non-myeloid cells in some disease states. The functional –463GA promoter polymorphism alters MPO expression levels. The –463G is within an SP1 binding site and is associated with higher gene expression. The G allele is most frequent with ~62 % of European populations being GG homozygotes. The GA polymorphism has been associated with risk or survival in a variety of cancers including lung and breast cancer. In this study we determined the frequency of the –463G/A polymorphism in 230 ovarian cancer patients, 75 patients with borderline ovarian tumors, and 299 healthy controls. The GG genotype was found to be overrepresented in patients with early stage ovarian cancer (83.3 % GG, p = 0.008) as compared to healthy controls (62 % GG), suggesting that MPO oxidants may increase risk. Immunohistochemical analysis revealed MPO expression in a subset of columnar ovarian epithelial carcinoma cells in early stage carcinomas.

Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.PubMedCrossRef

Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8.PubMedCrossRef

Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 2012;72:2701–4.PubMedCrossRef

Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol: Off J U S Can Acad Pathol Inc. 2012;25:625–36.CrossRef

Minegishi K, Tanaka M, Nishimura O, Tanigaki S, Miyakoshi K, Ishimoto H, et al. Reactive oxygen species mediate leukocyte–endothelium interactions in prostaglandin F2alpha-induced luteolysis in rats. Am J Physiol Endocrinol Metab. 2002;283:E1308–15.PubMed

Shirai F, Kawaguchi M, Yutsudo M, Dohi Y. Human peripheral blood polymorphonuclear leukocytes at the ovulatory period are in an activated state. Mol Cell Endocrinol. 2002;196:21–8.PubMedCrossRef

Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. J Soc Gynecol Investig. 2001;8:S40–2.PubMedCrossRef

Van Rensburg CE, Van Staden AM, Anderson R, Van Rensburg EJ. Hypochlorous acid potentiates hydrogen peroxide-mediated DNA-strand breaks in human mononuclear leucocytes. Mutat Res. 1992;265:255–61.PubMedCrossRef

Gomez-Mejiba SE, Zhai Z, Gimenez MS, Ashby MT, Chilakapati J, Kitchin K, et al. Myeloperoxidase-induced genomic DNA-centered radicals. J Biol Chem. 2010;285:20062–71.PubMedCrossRef

10.

Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM: Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol. 2013;93:185–98.

11.

Arnhold J, Flemmig J. Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys. 2010;500:92–106.PubMedCrossRef

12.

Rossmann C, Rauh A, Hammer A, Windischhofer W, Zirkl S, Sattler W, et al. Hypochlorite-modified high-density lipoprotein promotes induction of HO-1 in endothelial cells via activation of p42/44 MAPK and zinc finger transcription factor Egr-1. Arch Biochem Biophys. 2011;509:16–25.PubMedCentralPubMedCrossRef

13.

Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, et al. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of alzheimer disease. J Biol Chem. 2009;284:3158–69.PubMedCrossRef

14.

Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol. 2000;7:53–8.PubMedCrossRef

15.

Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF. Transgenic mice express human MPO –463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in –463G males. J Lipid Res. 2006;47:1366–77.PubMedCrossRef

16.

Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, et al. Neuronal expression of myeloperoxidase is increased in alzheimer's disease. J Neurochem. 2004;90:724–33.PubMedCrossRef

17.

Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176–84.PubMedCrossRef

18.

Malle E, Marsche G, Arnhold J, Davies MJ. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta. 2006;1761:392–415.PubMedCrossRef

19.

Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, et al. MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology. 2000;55:1284–90.PubMedCrossRef

20.

Yuzhalin AE, Kutikhin AG. Common genetic variants in the myeloperoxidase and paraoxonase genes and the related cancer risk: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30:287–322.PubMedCrossRef

21.

Saed GM, Ali-Fehmi R, Jiang ZL, Fletcher NM, Diamond MP, Abu-Soud HM, et al. Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol. 2010;116:276–81.PubMedCentralPubMedCrossRef

22.

Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, et al. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol. 2004;93:615–20.PubMedCrossRef

23.

Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, et al. Myeloperoxidase and free iron levels: potential biomarkers for early detection and prognosis of ovarian cancer. Cancer Biomark Sect A Dis Markers. 2011;10:267–75.

24.

Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase —463g–>a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181–4.PubMed

25.

Pabalan N, Jarjanazi H, Sung L, Li H, Ozcelik H. Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis. PLoS One. 2012;7:e32389.PubMedCentralPubMedCrossRef

26.

Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood. 1997;90:2730–7.PubMed

27.

Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res. 2005;65:1105–11.PubMed

28.

Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, et al. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:4973–9.CrossRef

29.

Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant—463A of the myeloperoxidase gene. Cancer Res. 2000;60:644–9.PubMed

30.

Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, et al. Point: Myeloperoxidase –463G –>A polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1550–4.PubMed

31.

Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, Gunn GB, et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer. 2002;37:35–40.PubMedCrossRef

32.

Vansant G, Reynolds WF. The consensus sequence of a major alu subfamily contains a functional retinoic acid response element. Proc Natl Acad Sci U S A. 1995;92:8229–33.PubMedCentralPubMedCrossRef

33.

Reynolds WF, Kumar AP, Piedrafita FJ. The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands. Biochem Biophys Res Commun. 2006;349:846–54.PubMedCentralPubMedCrossRef

34.

Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996;271:14412–20.PubMedCrossRef

35.

Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the –463GA promoter polymorphism. J Biol Chem. 2004;279:8300–15.PubMedCrossRef

36.

Van Schooten FJ, Boots AW, Knaapen AM, Godschalk RW, Maas LM, Borm PJ, et al. Myeloperoxidase (MPO) –463G-> A reduces mpo activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev. 2004;13:828–33.PubMed

37.

van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal. 2009;11:2899–937.PubMedCrossRef

38.

Song M, Santanam N. Increased myeloperoxidase and lipid peroxide-modified protein in gynecological malignancies. Antioxid Redox Signal. 2001;3:1139–46.PubMedCrossRef

39.

Reynolds WF, Stegeman CA. Tervaert JW: –463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol. 2002;103:154–60.PubMedCrossRef

40.

Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Shih Ie M: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218–24.PubMedCrossRef

41.

Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol. 1999;155:31–41.PubMedCrossRef

42.

Spencer JP, Whiteman M, Jenner A, Halliwell B. Nitrite-induced deamination and hypochlorite-induced oxidation of DNA in intact human respiratory tract epithelial cells. Free Radic Biol Med. 2000;28:1039–50.PubMedCrossRef

43.

Kensler TW, Egner PA, Moore KG, Taffe BG, Twerdok LE, Trush MA. Role of inflammatory cells in the metabolic activation of polycyclic aromatic hydrocarbons in mouse skin. Toxicol Appl Pharmacol. 1987;90:337–46.PubMedCrossRef

44.

Trush A, Esterline RL, Mallet WG, Mosebrook DR, Twerdok LE. Further evidence for the role of myeloperoxidase in the activation of benzo[a]pyrene-7,8-dihydrodiol by polymorphonuclear leukocytes. Adv Exp Med Biol. 1991;283:399–401.PubMedCrossRef

45.

Gungor N, Godschalk RW, Pachen DM, Van Schooten FJ, Knaapen AM. Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase. FASEB J Off Publ Fed Am Soc Exp Biol. 2007;21:2359–67.

46.

Gungor N, Knaapen AM, Munnia A, Peluso M, Haenen GR, Chiu RK, et al. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis. 2010;25:149–54.PubMedCrossRef

47.

Pero RW, Sheng Y, Olsson A, Bryngelsson C, Lund-Pero M. Hypochlorous acid/n-chloramines are naturally produced DNA repair inhibitors. Carcinogenesis. 1996;17:13–8.PubMedCrossRef

48.

Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, Rossi G, et al. Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:2291–7.PubMedCrossRef

49.

Rainis T, Maor I, Lanir A, Shnizer S, Lavy A. Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci. 2007;52:526–30.PubMedCrossRef

50.

Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase –463G>A polymorphism and risk of primary lung cancer in a korean population. Cancer Detect Prev. 2006;30:257–61.PubMedCrossRef

51.

Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163–6.PubMedCrossRef

52.

Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, et al. Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk. Cancer Res. 2004;64:7634–9.PubMedCrossRef

53.

Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973–8.PubMedCrossRef

Titel: Association of myeloperoxidase with ovarian cancer
verfasst von: Dan Cacsire Castillo-Tong
Dietmar Pils
Georg Heinze
Ioana Braicu
Jalid Sehouli
Alexander Reinthaller
Eva Schuster
Andrea Wolf
Rafal Watrowski
Richard A. Maki
Robert Zeillinger
Wanda F. Reynolds
Publikationsdatum: 01.01.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 1/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1017-3

Springer Medizin

Association of myeloperoxidase with ovarian cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells

MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2

SMAD4 is a potential prognostic marker in human breast carcinomas

Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis

Quantitative assessment of the association between +61A>G polymorphism of epidermal growth factor gene and susceptibility to glioma

The association of SIPA1 gene polymorphisms with breast cancer risk: evidence from published studies

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie